These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Nitta E; Izutsu K; Sato T; Ota Y; Takeuchi K; Kamijo A; Takahashi K; Oshima K; Kanda Y; Chiba S; Motokura T; Kurokawa M Ann Oncol; 2007 Feb; 18(2):364-9. PubMed ID: 17079695 [TBL] [Abstract][Full Text] [Related]
6. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Wolach O; Bairey O; Lahav M Medicine (Baltimore); 2010 Sep; 89(5):308-318. PubMed ID: 20827108 [TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
8. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868 [TBL] [Abstract][Full Text] [Related]
9. VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience. Ishii K; Urase F; Nagare Y; Kimura H; Manabe M; Yagi T; Teshima H; Hayashi K; Shibano M; Tsukaguchi M; Katsurada T; Mugitani A; Kitayama H; Nomura S Arch Gerontol Geriatr; 2010; 51(2):209-15. PubMed ID: 19926148 [TBL] [Abstract][Full Text] [Related]
10. Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma. Arai Y; Yamashita K; Mizugishi K; Nishikori M; Hishizawa M; Kondo T; Kitano T; Kawabata H; Kadowaki N; Takaori-Kondo A Hematology; 2015 May; 20(4):196-202. PubMed ID: 25130775 [TBL] [Abstract][Full Text] [Related]
11. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435 [TBL] [Abstract][Full Text] [Related]
12. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Tesfa D; Gelius T; Sander B; Kimby E; Fadeel B; Palmblad J; Hägglund H Med Oncol; 2008; 25(4):374-9. PubMed ID: 18278570 [TBL] [Abstract][Full Text] [Related]
13. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy. Barreto JN; Ice LL; Thompson CA; Tosh PK; Osmon DR; Dierkhising RA; Plevak MF; Limper AH Am J Hematol; 2016 Nov; 91(11):1113-1117. PubMed ID: 27472910 [TBL] [Abstract][Full Text] [Related]
14. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Lai GG; Lim ST; Tao M; Chan A; Li H; Quek R Am J Hematol; 2009 Jul; 84(7):414-7. PubMed ID: 19415727 [TBL] [Abstract][Full Text] [Related]
15. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153 [TBL] [Abstract][Full Text] [Related]
16. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Wilson WH; Gutierrez M; O'Connor P; Frankel S; Jaffe E; Chabner BA; Grossbard ML Semin Oncol; 2002 Feb; 29(1 Suppl 2):41-7. PubMed ID: 11842388 [TBL] [Abstract][Full Text] [Related]
17. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858 [TBL] [Abstract][Full Text] [Related]
18. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. Khouri IF; Saliba RM; Hosing C; Okoroji GJ; Acholonu S; Anderlini P; Couriel D; De Lima M; Donato ML; Fayad L; Giralt S; Jones R; Korbling M; Maadani F; Manning JT; Pro B; Shpall E; Younes A; McLaughlin P; Champlin RE J Clin Oncol; 2005 Apr; 23(10):2240-7. PubMed ID: 15800314 [TBL] [Abstract][Full Text] [Related]
19. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Sparano JA; Lee JY; Kaplan LD; Levine AM; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Von Roenn J; Dezube BJ; Remick SC; Shah MH; Leichman L; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R; Blood; 2010 Apr; 115(15):3008-16. PubMed ID: 20023215 [TBL] [Abstract][Full Text] [Related]
20. Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. Rozman S; Sonc M; Novakovic BJ Leuk Lymphoma; 2012 Oct; 53(10):1945-8. PubMed ID: 22563814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]